312 related articles for article (PubMed ID: 21523499)
41. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Ryan DP; Kulke MH; Fuchs CS; Grossbard ML; Grossman SR; Morgan JA; Earle CC; Shivdasani R; Kim H; Mayer RJ; Clark JW
Cancer; 2002 Jan; 94(1):97-103. PubMed ID: 11815964
[TBL] [Abstract][Full Text] [Related]
42. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA
Cancer Invest; 2008 Feb; 26(1):47-52. PubMed ID: 18181045
[TBL] [Abstract][Full Text] [Related]
43. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery.
Miyasaka Y; Ohtsuka T; Kimura R; Matsuda R; Mori Y; Nakata K; Kakihara D; Fujimori N; Ohno T; Oda Y; Nakamura M
Ann Surg Oncol; 2019 May; 26(5):1528-1534. PubMed ID: 30868514
[TBL] [Abstract][Full Text] [Related]
44. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma.
Ielpo B; Caruso R; Duran H; Diaz E; Fabra I; Malavé L; Ferri V; Alvarez R; Cubillo A; Plaza C; Lazzaro S; Kalivaci D; Quijano Y; Vicente E
Surg Oncol; 2017 Dec; 26(4):402-410. PubMed ID: 29113659
[TBL] [Abstract][Full Text] [Related]
45. Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
Ajouz H; Mukherji D; Haydar A; Yakan AS; Saleh A; Elias E; Temraz S; Faraj W; Khalife M; Shamseddine A
J Gastrointest Cancer; 2014 Mar; 45(1):109-12. PubMed ID: 24362621
[TBL] [Abstract][Full Text] [Related]
46. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
Ielpo B; Duran H; Diaz E; Fabra I; Caruso R; Ferri V; Malavé L; Hidalgo M; Alvarez R; Plaza C; Quijano Y; Vicente E
Eur J Surg Oncol; 2016 Sep; 42(9):1394-400. PubMed ID: 26899943
[TBL] [Abstract][Full Text] [Related]
47. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
[TBL] [Abstract][Full Text] [Related]
48. Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
Jacobs AD; Otero H; Picozzi VJ; Aboulafia DM
Cancer Invest; 2004; 22(4):505-14. PubMed ID: 15565807
[TBL] [Abstract][Full Text] [Related]
49. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Lutz MP; Van Cutsem E; Wagener T; Van Laethem JL; Vanhoefer U; Wils JA; Gamelin E; Koehne CH; Arnaud JP; Mitry E; Husseini F; Reichardt P; El-Serafi M; Etienne PL; Lingenfelser T; Praet M; Genicot B; Debois M; Nordlinger B; Ducreux MP;
J Clin Oncol; 2005 Dec; 23(36):9250-6. PubMed ID: 16361622
[TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.
Heinrich S; Schäfer M; Weber A; Hany TF; Bhure U; Pestalozzi BC; Clavien PA
Ann Surg; 2008 Dec; 248(6):1014-22. PubMed ID: 19092346
[TBL] [Abstract][Full Text] [Related]
51. Pancreatic Cancer in the Era of Neoadjuvant Therapy: A Narrative Overview.
Casciani F; Marchegiani G; Malleo G; Bassi C; Salvia R
Chirurgia (Bucur); 2018; 113(3):307-317. PubMed ID: 29981662
[TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
[TBL] [Abstract][Full Text] [Related]
53. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Nakagawa N; Sueda T
J Surg Oncol; 2012 Aug; 106(2):174-80. PubMed ID: 22331838
[TBL] [Abstract][Full Text] [Related]
54. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Saif MW; Syrigos K; Penney R; Kaley K
Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
[TBL] [Abstract][Full Text] [Related]
55. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Reni M; Cereda S; Rognone A; Belli C; Ghidini M; Longoni S; Fugazza C; Rezzonico S; Passoni P; Slim N; Balzano G; Nicoletti R; Cappio S; Doglioni C; Villa E
Cancer Chemother Pharmacol; 2012 Jan; 69(1):115-23. PubMed ID: 21626049
[TBL] [Abstract][Full Text] [Related]
56. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
[TBL] [Abstract][Full Text] [Related]
57. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis.
Yoo C; Lee SS; Song KB; Jeong JH; Hyung J; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Lee SS; Kim JH; Jin HS; Park JH; Hwang DW; Lee JH; Lee W; Chang HM; Kim KP; Ryoo BY; Kim SC
Br J Cancer; 2020 Aug; 123(3):362-368. PubMed ID: 32433600
[TBL] [Abstract][Full Text] [Related]
58. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
[TBL] [Abstract][Full Text] [Related]
59. Survival benefit with the combination of docetaxel, gemcitabine and erlotinib in advanced and/or metastatic pancreatic cancer patients.
Samelis GF; Ekmektzoglou K; Tsiakou A; Giannakaki S; Konstadoulakis M
Hepatogastroenterology; 2011; 58(110-111):1776-81. PubMed ID: 21940348
[TBL] [Abstract][Full Text] [Related]
60. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Wilkowski R; Thoma M; Bruns C; Wagner A; Heinemann V
JOP; 2006 Jul; 7(4):349-60. PubMed ID: 16832132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
